Please find enclosed a copy of the Unaudited Financial Results for the Quarter ended 31st March 2026
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 28 Apr 2026, 06:36 PM IST · BSE ID: 7f9a325b-56a9-4361-8d21-79ef88dd34d9
View Original BSE Filing (PDF)
💡
In Simple Terms
Sanofi India's diabetes insulin business grew 19% in Q4 as expected; board replaced two retiring independent directors and restructured all board committees.
🤖 AI Summary
- Q4 FY26 insulin portfolio revenue ₹4,723 Million, grew 19% YoY and 14% quarter-on-quarter
- Two independent directors—Aditya Narayan and Usha Thorat—tenure ended 29 April 2026
- Rahul Bhatnagar appointed board chairman from 30 April 2026
- All five board committees reconstituted; Rajani Kesari and Siraj Chaudhry hold multiple chairmanships
- Quarter results impacted by partnership transitions; export sales stabilizing amid geopolitical headwinds
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations Q4 FY26
₹4,723 Million
-12.2%
Insulin Portfolio Growth YoY
19%
Insulin Portfolio Growth Sequential
14%
Total Income Q4 FY26
₹4,767 Million
-11.6%
Cost of Materials Consumed Q4
₹503 Million
-33.6%
🏢 How This Affects the Company
Insulin portfolio demonstrated sustained double-digit growth momentum (19% YoY, 14% sequentially), validating market position in diabetes injectables despite competitive pressure from newer therapies. Strategic partnerships in cardiovascular, oral anti-diabetes, and CNS segments provide diversification, though current-quarter results were dampened by partnership transition costs.
Total income Q4 FY26: ₹4,767 Million versus ₹5,392 Million prior year (down 11.6%), driven by revenue decline from ₹5,359 Million to ₹4,723 Million. Decline attributable to partnership transition transactions and prior-year comparisons, not core insulin portfolio weakness.
Board reconstitution and appointment of new chairman signal governance continuity. Rajani Kesari and Siraj Chaudhry assume expanded committee roles, indicating reliance on core independent director skill sets across audit, risk, remuneration, and CSR functions.
Partnership transitions created material Q4 headwinds and clouded underlying business performance visibility. Export sales stabilization claim amid geopolitical uncertainty requires monitoring for sustained margin pressure.
👥 What This Means For Shareholders
✅
Action Required
No action required. Results filing is routine disclosure; board changes are governance routine disclosed under Reg 30.
👤
Who Is Affected
All equity shareholders. Revenue decline 11.6% YoY to ₹4,767 Million impacts earnings per share proportionally. Partnership transitions are non-recurring; core insulin performance unaffected.
🔍
Management Signal
Appointment of independent director as chairman and expanded committee roles signal stable governance and management continuity through partnership transition period.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — confirm if partnership transitions are complete and revenue stabilizes above ₹4,500 Million
Board committee meetings minutes — track if new chairman Bhatnagar initiates strategic or operational changes
Export sales trends next quarter — validate management's 'stabilization' claim amid ongoing geopolitical headwinds
MEDIUM RISK
Partnership transitions masked underlying performance; export sales fragile; revenue declined 12.2% YoY. Visibility into Q1 FY27 execution critical.
💡 Investor Takeaway
Q4 FY26 insulin portfolio reached ₹4,723 Million (19% YoY growth), validating core segment strength. Total income fell 11.6% YoY to ₹4,767 Million due to partnership transition costs and export headwinds. Board reconstitution completed with Rahul Bhatnagar appointed chairman. Monitor Q1 FY27 for partnership benefit realization and export stabilization confirmation.
⚖️ Strengths & Concerns
✅ Positives
- Insulin portfolio revenue ₹4,723 Million represents 19% YoY and 14% sequential growth despite market headwinds
- Domestic market double-digit insulin growth consecutive two quarters validates clinical positioning and physician trust
⚠️ Concerns
- Total income declined 11.6% YoY to ₹4,767 Million; partnership transitions materially dampened Q4 reported results
- Export sales described as 'stabilizing' only—implies fragility amid geopolitical situation and ongoing margin compression
📅 Company Track Record
Sanofi India's insulin franchise has been core to earnings. Past filing context shows consistent insulin portfolio strength; this quarter's YoY revenue decline attributable to non-recurring partnership costs, not market share loss. Domestic insulin segment remains strategic focus.
Based on publicly available historical data. For context only.